Interpretation of Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update(Version 2019)
10.19538/j.cjps.issn1005-2208.2019.12.03
- Author:
Yu-hang SUI
1
;
Ji-sheng HU
1
;
Bei SUN
1
Author Information
1. Department of Pancreatic and Biliary Surgery,the First Affiliated Hospital of Harbin Medical University, Key Laboratory of Hepatosplenic Surgery, Ministry of Education Haerbin 150001, China
- Publication Type:Journal Article
- Keywords:
potentially curable;
pancreatic cancer;
clinical practice guideline
- From:
Chinese Journal of Practical Surgery
2019;39(12):1254-1256
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is one of the most malignancy tumor in digestive system with extraordinarily poor prognosis owing to its difficulty in early diagnosis and complex treatments.Recently,great progress has been made in surgical techniques,adjuvant treatment and perioperative management of pancreatic cancer.However,the long-term survival of patients with pancreatic cancer has not been significantly improved. American Society of Clinical Oncology released clinical practice guidelines for potentially curable pancreatic cancer in 2016 and updated it for the first time in 2017.In2019,American Society of Clinical Oncology renewed its guidelines in order to modify the program of postoperative adjuvant therapy for pancreatic cancer and recommend FOLFIRINOX as the first choice for postoperative adjuvant therapy for patients with pancreatic cancer in order to improve the prognosis of patients with pancreatic cancer.
